Yoko J. Bian, PhD’s Post

Join my colleagues and me as we delve into diverse hot topics in Chemistry and the Law at the American Chemical Society Spring Conference this afternoon in New Orleans. Natasha Daughtrey Eric Romeo Olivia D. Uitto, Ph.D, J.D. Gabriel Ferrante Miho Kaneko Christopher Haley #acsspring2024 ACS - Chemistry and the Law #IP #Litigation

Join Huiya Wu and I on Jan 30 as we discuss the players, products, and legal schemes of the biosimilars market in China, as well as an update on the patent linkage litigation. CLE credit will be offered. Registration link: https://lnkd.in/eA4HCkMw. #GoodwinLaw #PatentLitigation #IP #Litigation #biosimilars #China #market #webinar

As we settle into 2024, we reflect on the significant legal developments of 2023 that hold potential impact on the biologics and biosimilars market.  Here is a recap of some of the top five legal decisions and developments in the biosimilars and biologics space in 2023 that we covered on the Big Molecule Watch. #biosimilars #biologics #patent #litigation Regeneron Amgen Samsung Biologics REGENXBIO Inc.Celltrion Inc  Sarepta Therapeutics #EYLEA #InflationReductionAct #SOLIRIS #eculizumab #STELARA #ustekinumab #PRALUENT #ustekinumab #aflibercept #eculizumab

Those familiar with my stance are aware of my support for hardworking blue-collar Americans in various sectors. If you're interested in understanding the potential effects of AI on factory workers and the corresponding legal considerations from a manufacturer’s standpoint, I encourage you to give this piece a quick look. Many thanks to Jessica Pauley for her contributions over the summer. #AI #manufacturing #dataprivacy

Regeneron sues Samsung Bioepis for proposed biosimilar of EYLEA in the U.S. District Court for the Northern District of West Virginia. This is the third infringement suit under the BPCIA concerning a proposed biosimilar of EYLEA, after Regeneron sued Mylan and Celltrion Inc. on August 3, 2022, and Nov 8, 2023, respectively. #EYLEA #aflibercept #biosimilars #BPCIA #litigation

UK Authorizes World-First Gene Therapy from Vertex Pharmaceuticals and CRISPR Therapeutics for Blood Disorders #CRISPR #CASGEVY #genetherapy #sicklecelldisease #MHRA #FDA

Generic and biosimilar drugs saved $408B for America's patients and healthcare system in 2022. #biosimilars #generics #prescriptiondrugs #medicare #healthcare #lifesciences

In the last week, seven adalimumab biosimilars referencing HUMIRA entered the U.S. market: Boehringer Ingelheim’s CYLTEZO; Sandoz’s HYRIMOZ; Organon and Samsung Bioepis’s HADLIMA; Coherus BioSciences's YUSIMRY; Celltrion Inc.’s YUFLYMA; Fresenius Kabi’s IDACIO; and Biocon’s HULIO. #adalimumab #HUMIRA #biosimilars #lifesciences